Pharma Focus Asia

Vertex Plans to Open New Clinical Manufacturing Facility

Introduction:
Vertex Pharmaceuticals Incorporated plans for the construction of new manufacturing facility. The site will be loacted at Boston Seaport, US.

Features:
The new state-of-the-art cell and genetic therapies research and clinical manufacturing site is laid with an area covering 344,000 square foot. This construction is developed in partnership with Related Beal, Boston Real Estate Inclusion Fund and Kavanagh Advisory group.

The facility features labs, offices and manufacturing capabilities dedicated for cell and genetic therapies research and clinical manufacturing thus supporting the fast growth.

After the completion, the two buildings Jeffrey Leiden Center for Cell and Genetic Therapies I (Leiden I) and Planned Leiden Center Expansion (20-22 Drydock Avenue) (Leiden II) will be known as Leiden Campus supporting various disease areas, spanning multiple modalities and helping the research and developement teams in bringing transformative therapies to patients.

The new manufacturing site is expected to create new job opportunities for additional 500 employees and begin its operations in 2025.

Specifications:

NameVertex
TypeNew Construction
Year2025
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference